P B Berger

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial
    P B Berger
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
    Circulation 100:14-20. 1999
  2. ncbi Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation
    P B Berger
    Division of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 38:1440-9. 2001
  3. ncbi C-reactive protein levels are influenced by common IL-1 gene variations
    Peter Berger
    Division of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cytokine 17:171-4. 2002
  4. ncbi Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (
    Peter B Berger
    Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 143:841-6. 2002
  5. ncbi Frequency of early occlusion and stenosis in a left internal mammary artery to left anterior descending artery bypass graft after surgery through a median sternotomy on conventional bypass: benchmark for minimally invasive direct coronary artery bypass
    P B Berger
    Division of Cardiovascular Diseases and the Section of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Circulation 100:2353-8. 1999
  6. ncbi Hyperhomocysteinemia: an important risk factor for cardiovascular disease? Not yet!
    P Berger
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thromb Haemost 1:1876-7. 2003
  7. ncbi Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective
    Peter B Berger
    Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 106:2284-7. 2002
  8. ncbi One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial
    P B Berger
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Circulation 99:873-8. 1999
  9. ncbi Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement
    P B Berger
    Division of Cardiovascular Diseases, Department of Internal Medicine and the Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
    Circulation 99:248-53. 1999
  10. ncbi The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial
    Peter B Berger
    Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 149:869-75. 2005

Detail Information

Publications83

  1. ncbi Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial
    P B Berger
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
    Circulation 100:14-20. 1999
    ....
  2. ncbi Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation
    P B Berger
    Division of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 38:1440-9. 2001
    ..We sought to compare survival after coronary artery bypass graft (CABG) and percutaneous transluminal coronary angioplasty (PTCA) in high-risk anatomic subsets...
  3. ncbi C-reactive protein levels are influenced by common IL-1 gene variations
    Peter Berger
    Division of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cytokine 17:171-4. 2002
    ..These data indicate that IL-1 gene polymorphisms known to affect the inflammatory response are highly related to plasma levels of CRP and fibrinogen in patients referred for coronary angiography...
  4. ncbi Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (
    Peter B Berger
    Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 143:841-6. 2002
    ..Controversy exists regarding the frequency of late stent thrombosis among patients treated with intracoronary stents and the most appropriate duration of treatment with a thienopyridine that is required to prevent this complication...
  5. ncbi Frequency of early occlusion and stenosis in a left internal mammary artery to left anterior descending artery bypass graft after surgery through a median sternotomy on conventional bypass: benchmark for minimally invasive direct coronary artery bypass
    P B Berger
    Division of Cardiovascular Diseases and the Section of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Circulation 100:2353-8. 1999
    ..The issue has gained importance for comparison with less invasive surgical approaches in which operative exposure may be limited and graft anastomosis more difficult...
  6. ncbi Hyperhomocysteinemia: an important risk factor for cardiovascular disease? Not yet!
    P Berger
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thromb Haemost 1:1876-7. 2003
  7. ncbi Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective
    Peter B Berger
    Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 106:2284-7. 2002
  8. ncbi One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial
    P B Berger
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Circulation 99:873-8. 1999
    ....
  9. ncbi Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement
    P B Berger
    Division of Cardiovascular Diseases, Department of Internal Medicine and the Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
    Circulation 99:248-53. 1999
    ..However, ticlopidine causes neutropenia in 1% of patients when administered for >2 weeks, and little is known about the duration that ticlopidine needs be administered to prevent stent thrombosis...
  10. ncbi The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial
    Peter B Berger
    Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 149:869-75. 2005
    ..In particular, whether outcome differences exist between agents that are renally excreted (tirofiban) or not (abciximab) in patients with mild renal impairment is not known...
  11. ncbi Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An
    P B Berger
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 96:122-7. 1997
    ....
  12. ncbi Influence of procedural success on immediate and long-term clinical outcome of patients undergoing percutaneous revascularization of occluded coronary artery bypass vein grafts
    P B Berger
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 28:1732-7. 1996
    ..This study sought to determine whether successful recanalization of an occluded vein graft is associated with improvement in long-term clinical outcome...
  13. ncbi Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA)
    P B Berger
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 142:776-81. 2001
    ..Whether ticlopidine is beneficial after balloon angioplasty is unknown. Our purpose was to compare the clinical outcome of patients undergoing balloon angioplasty treated with both aspirin and ticlopidine versus aspirin alone...
  14. ncbi Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction
    S H Wilson
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 141:704-10. 2001
    ..6; P <.0001). CONCLUSIONS: Reocclusion after PTCA and stent placement during AMI is less frequent than after thrombolysis. This may contribute to the superior outcome of patients treated with PTCA and stent placement in this setting...
  15. ncbi Comparison of percutaneous interventions for unstable angina pectoris in patients with and without previous coronary artery bypass grafting
    V Mathew
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Cardiol 86:931-7. 2000
    ..In patients who underwent previous CABG, treatment of native lesions affords better long-term outcome than vein graft intervention...
  16. ncbi Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting
    J Al Suwaidi
    Division of Cardiovascular Diseases and the Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn, USA
    Am Heart J 142:452-9. 2001
    ..96-1.56], P =.11). CONCLUSIONS: Primary PCI for AMI in patients with previous CABG is associated with higher adverse events largely attributable to adverse baseline clinical characteristics and the treatment of a vein graft...
  17. ncbi Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab
    A V Cote
    Department of Anesthesiology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 76:890-6. 2001
    ..CONCLUSION: In this clinical setting, use of adjunctive abciximab during percutaneous coronary intervention was associated with a significantly increased risk of both major and minor bleeding...
  18. ncbi Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation
    D R Holmes
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Circulation 100:2067-73. 1999
    ..This study assessed the incidence and outcomes of cardiogenic shock developing after enrollment among patients with and without ST-segment elevation in the Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO)-IIb trial...
  19. ncbi Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure
    H H Ting
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Cardiol 87:630-3, A9. 2001
    ..9% for the control group, 16.2% for the group with CRF, and 14.1% for dialysis patients. Cardiac mortality at 1 year was 1.9% for ther control group, 15.2% for the group with CRF, and 10.0% for dialysis patients...
  20. ncbi Effect of abciximab on the outcome of emergency coronary artery bypass grafting after failed percutaneous coronary intervention
    M Singh
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 76:784-8. 2001
    ..However, in-hospital adverse events are infrequent and comparable to those for patients who do not receive abciximab...
  21. ncbi Intercenter variability in outcome for patients treated with direct coronary angioplasty during acute myocardial infarction
    T F Christian
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am Heart J 135:310-7. 1998
    ..The purpose of this study was to investigate the impact of the center performing direct coronary angioplasty for acute myocardial infarction while controlling for parameters known to affect outcome...
  22. ncbi Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience)
    M Singh
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Cardiol 88:1091-6. 2001
    ..Despite improvement in the outcome of patients with thrombus undergoing PCI in recent years, thrombus is still an independent predictor of adverse in-hospital outcomes after PCI...
  23. ncbi Threshold values for preserved viability with a noninvasive measurement of collateral blood flow during acute myocardial infarction treated by direct coronary angioplasty
    T F Christian
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Circulation 100:2392-5. 1999
    ..The purpose of this study was to determine whether a viability threshold could be identified from this measure in patients with acute myocardial infarction treated in a homogeneous manner with successful reperfusion therapy...
  24. ncbi Restrictive cardiomyopathy associated with the eosinophilia-myalgia syndrome
    P B Berger
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic Rochester, MN 55905
    Mayo Clin Proc 69:162-5. 1994
    ..CONCLUSION: Restrictive cardiomyopathy may occur in the setting of the eosinophilia-myalgia syndrome and should be considered in patients with this disease in whom exertional dyspnea and peripheral edema occur...
  25. ncbi One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel
    Albert Schomig
    Deutsches Herzzentrum, Lazarettstr 36, 80636 Munich, Germany
    Eur Heart J 26:1379-84. 2005
    ..We assessed whether there was any clinical benefit from abciximab at 1 year follow-up...
  26. ncbi Variability in platelet responsiveness to clopidogrel among 544 individuals
    Victor L Serebruany
    HeartDrug Research Laboratories, Osler Medical Building, 7600 Osler Drive, Towson, MD 21204, USA
    J Am Coll Cardiol 45:246-51. 2005
    ..We sought to describe the responses of patients to clopidogrel using ex vivo measures of platelet aggregation and activation in a large, heterogeneous population...
  27. ncbi Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial)
    Victor Bernardi
    Clínica del Sol, Buenos Aires, Argentina
    Am J Cardiol 99:349-52. 2007
    ..In conclusion, after successful placement of a bare metal stent in a coronary artery, patients treated with 6 months of clopidogrel showed a trend toward fewer adverse events compared with those treated for 30 days...
  28. ncbi Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals
    Glenn N Levine
    Baylor College of Medicine, Houston, Texas, USA
    Pharmacotherapy 26:1537-56. 2006
    ..In this guide, the newer antiplatelet and antithrombin drugs that may be used during PCI are reviewed, and recommendations regarding the proper administration of these agents are provided...
  29. ncbi Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial
    Adnan Kastrati
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany
    JAMA 295:1531-8. 2006
    ....
  30. ncbi Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events...
  31. ncbi Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention
    Steven R Steinhubl
    Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    J Am Coll Cardiol 47:939-43. 2006
    ..This study sought to determine the optimal timing of a 300-mg clopidogrel loading dose before percutaneous coronary intervention (PCI) in patients enrolled in the Clopidogrel for the Reduction of Events During Observation (CREDO) trial...
  32. ncbi A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:401. 2005
    ..We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis...
  33. ncbi Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease
    Sotirios Tsimikas
    Division of Cardiovascular Diseases, University of California, San Diego, La Jolla, CA 92093 0682, USA
    N Engl J Med 353:46-57. 2005
    ....
  34. ncbi Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopen
    E Magnus Ohman
    Division of Cardiology, Division of Hematology, and School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599 7075, USA
    J Thromb Thrombolysis 19:11-9. 2005
    ..Both HIT and HITT are associated with high morbidity and mortality and represent substantial worldwide public health concerns...
  35. ncbi Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association
    Alexandra J Lansky
    Circulation 111:940-53. 2005
    ..This statement reviews sex-specific data on the safety and efficacy of contemporary interventional therapies in women...
  36. ncbi Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study
    Deepak Talreja
    Division of Cardiovascular Diseases, Mayo Clinic, W16, 200 First Street SW, Rochester, MN 55905, USA
    J Thromb Thrombolysis 18:25-30. 2004
    ..Given the frequent coadministration of these two medications, we sought to examine their interaction and their combined effect on platelet inhibition...
  37. ncbi Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  38. ncbi Perioperative management of patients with coronary stents
    Emmanouil S Brilakis
    Division of Cardiovascular Diseases, University of Texas Southwestern Medical Center, and Dallas VA Medical Center, Dallas, Texas 75216, USA
    J Am Coll Cardiol 49:2145-50. 2007
    ..Based on these published data, we offer recommendations that can be used to guide the treatment of patients who require noncardiac surgery after having received a stent...
  39. ncbi Bivalirudin versus unfractionated heparin during percutaneous coronary intervention
    Adnan Kastrati
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany
    N Engl J Med 359:688-96. 2008
    ..Whether bivalirudin is superior to unfractionated heparin in patients with stable or unstable angina who undergo percutaneous coronary intervention (PCI) after pretreatment with clopidogrel is unknown...
  40. ncbi The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Richard C Becker
    Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Chest 133:776S-814S. 2008
    ..For primary prevention in patients with moderate risk for a coronary event, we recommend aspirin, 75-100 mg/d, over either no antithrombotic therapy or vitamin K antagonist (Grade 1A)...
  41. ncbi The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    James D Douketis
    McMaster University, Hamilton, Ontario, Canada
    Chest 133:299S-339S. 2008
    ....
  42. doi The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
    Patricia J M Best
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 155:687-93. 2008
    ..Therapy with clopidogrel decreases adverse events in large patient populations. Therefore, we sought to determine the efficacy and safety of long-term clopidogrel therapy in patients with CKD...
  43. doi Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial
    Robert G Hart
    Department of Neurology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Cerebrovasc Dis 25:344-7. 2008
    ..Aspirin offers modest reduction in stroke in patients with atrial fibrillation. Whether combination of aspirin with clopidogrel offers additional protection is unclear...
  44. doi Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point
    Gjin Ndrepepa
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany
    J Am Coll Cardiol 51:690-7. 2008
    ....
  45. ncbi One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial
    Gjin Ndrepepa
    Deutsches Herzzentrum, Technische Universitat, Lazarettstrasse 36, 80636 Munich, Germany
    Eur Heart J 29:455-61. 2008
    ....
  46. ncbi Bleeding is bad.... isn't it?
    Peter B Berger
    Circulation 116:2776-8. 2007
  47. ncbi Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment
    Raisuke Iijima
    Deutsches Herzzentrum, Technische Universitat, Lazarettstr 36, 80636, Munich, Germany
    Clin Res Cardiol 97:160-8. 2008
    ....
  48. ncbi The risk of drug-eluting stent thrombosis with noncardiac surgery
    Emmanouil S Brilakis
    Dallas VA Medical Center, Dallas, TX 75216, USA
    Curr Cardiol Rep 9:406-11. 2007
    ..Preoperative identification and close monitoring of patients with DES may allow prevention and prompt detection and treatment of this catastrophic complication...
  49. ncbi Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44122, USA
    J Invasive Cardiol 19:287-90. 2007
    ..The relationship between target vessel revascularization (TVR) and ischemic events in patients treated with aspirin and clopidogrel or aspirin alone from 1 month to 1 year after PCI has not been studied...
  50. ncbi Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial
    Julinda Mehilli
    Deutsches Herzzentrum Technische Universität, Munich, Germany
    Am Heart J 154:158.e1-7. 2007
    ..It is not known whether there exists a sex-dependent difference in the clinical benefit of abciximab in patients with acute coronary syndromes (ACS) undergoing a percutaneous coronary intervention (PCI)...
  51. ncbi Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0284, USA
    Am Heart J 154:3-11. 2007
    ....
  52. ncbi Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 44:2133-6. 2004
    ..We examined clinical outcomes in the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) trial based on the duration of pretreatment with a 600-mg loading dose of clopidogrel...
  53. ncbi Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative
    Deepak L Bhatt
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine Desk F25, Cleveland, Ohio 44195, USA
    JAMA 292:2096-104. 2004
    ....
  54. ncbi Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
    Jacqueline Saw
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 108:921-4. 2003
    ..However, the clinical impact of this interaction has not been evaluated...
  55. ncbi Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions
    Patricia J M Best
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Am Heart J 146:345-50. 2003
    ..Abciximab reduces complications, but may cause excessive bleeding in patients with CRI. Therefore, we sought to determine the safety of abciximab in patients with CRI...
  56. ncbi Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)
    Thaddeus R Tolleson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 92:330-3. 2003
    ..These patients and their outcomes may be more representative of patients with typical acute coronary syndromes undergoing stenting in clinical practice...
  57. ncbi Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting
    Stephanie H Wilson
    Department of Cardiology, St Vincent s Hospital, Darlinghurst, Australia
    J Am Coll Cardiol 42:234-40. 2003
    ..We sought to determine the frequency and timing of complications at our institution when surgery was performed within two months of coronary stent placement...
  58. ncbi Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS)
    Mandeep Singh
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 107:2331-6. 2003
    ..Acolysis (therapeutic ultrasound) can break up thrombus in vitro in animal models and humans. Whether this is beneficial during percutaneous SVG interventions is unknown...
  59. ncbi Association of body mass index with outcome after percutaneous coronary intervention
    Brian D Powell
    Division of Cardiovascular Diseases and Internal Medicine and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Cardiol 91:472-6. 2003
  60. ncbi Safety and efficacy of cutting balloon angioplasty: the Mayo Clinic experience
    James L Orford
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Invasive Cardiol 14:720-4. 2002
    ..A number of evolving clinical indications for cutting balloon angioplasty (CBA) have been described in the clinical literature, including angioplasty-resistant stenoses, in-stent restenosis, ostial lesions and small vessel disease...
  61. ncbi Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
    Steven R Steinhubl
    Division of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Bldg, Chapel Hill, NC 27599, USA
    JAMA 288:2411-20. 2002
    ..Also, although current clinical data suggest a benefit for beginning therapy with a clopidogrel loading dose prior to PCI, the practical application of this therapy has not been prospectively studied...
  62. ncbi Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry
    James L Orford
    Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Am Coll Cardiol 40:1567-72. 2002
    ..The study examined the frequency, correlates, and outcome of patients with stent thrombosis within 30 days of stent placement...
  63. ncbi GUSTO V: should it affect clinical practice? Global Use of Strategies to Open Occluded Coronary Arteries
    James L Orford
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Cleve Clin J Med 69:520-2. 2002
  64. ncbi The thienopyridines
    Dieter F Lubbe
    Division of Cardiovascular Diseases, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    J Interv Cardiol 15:85-93. 2002
    ..However, for many patients with ACS, combination therapy is appropriate...
  65. ncbi Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention
    Charanjit S Rihal
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 105:2259-64. 2002
    ..In patients undergoing percutaneous coronary intervention (PCI) in the modern era, the incidence and prognostic implications of acute renal failure (ARF) are unknown...
  66. ncbi Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET)
    Albert W Chan
    Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
    J Am Coll Cardiol 42:1188-95. 2003
    ..We sought to examine if clopidogrel treatment initiated before coronary stenting improved clinical outcomes among patients receiving aspirin and a glycoprotein (GP) IIb/IIIa inhibitor...
  67. ncbi Clinical safety of magnetic resonance imaging early after coronary artery stent placement
    Thomas C Gerber
    Division of Cardiovascular Diseases, Mayo Clinic, Jacksonville, Florida 32224, USA
    J Am Coll Cardiol 42:1295-8. 2003
    ..Our aim was to examine the rate of adverse cardiac events in patients undergoing magnetic resonance imaging (MRI) <8 weeks after coronary stent placement...
  68. ncbi A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel
    Adnan Kastrati
    Deutsches Herzzentrum, Munich, Germany
    N Engl J Med 350:232-8. 2004
    ..Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel is unknown...
  69. ncbi Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial
    Patricia J M Best
    Mayo Clinic, Rochester, Minnesota, USA
    J Am Coll Cardiol 44:1786-91. 2004
    ..The goal of this study was to determine if restenosis is increased in mild and moderate chronic kidney disease (CKD) patients after percutaneous coronary intervention (PCI)...
  70. ncbi Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study
    Victor L Serebruany
    HeartDrug Research, LLC, Baltimore, MD, USA
    Arch Intern Med 164:2051-7. 2004
    ..We sought to address this issue prospectively by performing serial measurements of 19 platelet characteristics using conventional aggregometry, rapid analyzers, and flow cytometry...
  71. ncbi Routine intravascular ultrasound scanning guidance of coronary stenting is not associated with improved clinical outcomes
    James L Orford
    Division of Cardiovascular Medicine and Department of Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 148:501-6. 2004
    ..The purpose of the current study was to determine whether there is any incremental benefit to routine intravascular ultrasound (IVUS) guidance of percutaneous coronary intervention...
  72. ncbi Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention
    Jacqueline Saw
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 94:623-5. 2004
    ..4% vs 21.7%)...
  73. ncbi Cardiovascular disease and chronic kidney disease: insights and an update
    Patricia J M Best
    Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 148:230-42. 2004
    ..This review outlines our current understanding of CKD as a cardiovascular risk factor, treatment options, and the future directions that are needed to treat cardiovascular disease in patients with CKD...
  74. ncbi Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization
    Abhiram Prasad
    Division of Cardiovascular Diseases and Department of Internal Medicine, Rochester, Minn, USA
    Am Heart J 147:1066-70. 2004
    ..The applicability of this subset analysis from a select patient population enrolled in a randomized trial to the general population is unclear...
  75. ncbi Alveolar hemorrhage associated with periprocedural eptifibatide administration
    James L Orford
    Mayday University Hospital, Croydon, United Kingdom
    J Invasive Cardiol 16:341-2. 2004
  76. ncbi Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty
    Jassim Al Suwaidi
    Department of Cardiology and Cardiovascular Surgery, Hamad General Hospital and Hamad Medical Corporation, Doha, Qatar
    Am Heart J 147:815-22. 2004
    ..The aim of this study was to provide a quantitative comparison of the impact of coronary stenting on the rates of mortality and myocardial infarction with that of balloon angioplasty with provisional stenting...
  77. ncbi Independent association between plasma leptin and C-reactive protein in healthy humans
    Abu S M Shamsuzzaman
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, Rochester, Minn 55905, USA
    Circulation 109:2181-5. 2004
    ..We tested the hypothesis that leptin is associated with CRP levels independently of the influences of gender, body mass index (BMI), waist-to-hip ratio, and other variables...
  78. ncbi Resistance to antiplatelet drugs: is it real or relevant?
    Peter B Berger
    Division of Cardiovascular Diseases, Duke University Medical Center, Durham, North Carolina, USA
    Catheter Cardiovasc Interv 62:43-5. 2004
  79. ncbi Frequency and time course of reocclusion and restenosis in coronary artery occlusions after balloon angioplasty versus Wiktor stent implantation: results from the Mayo-Japan Investigation for Chronic Total Occlusion (MAJIC) trial
    Hideo Tamai
    Department of Cardiology, Shiga Medical Center for Adults, Moriyama, Japan
    Am Heart J 147:E9. 2004
    ..The purpose of this study was to examine the frequency and time course of restenosis and reocclusion after treatment of CTOs with balloon angioplasty and Wiktor stent implantation...
  80. ncbi Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation
    James L Orford
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 147:463-7. 2004
    ..We sought to determine the frequency and type of hemorrhagic complications in patients who undergo systemic anticoagulation with warfarin while receiving aspirin and clopidogrel after a PCI with stent placement...
  81. ncbi Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 39:9-14. 2002
    ..We sought to determine whether clopidogrel is at least as efficacious as ticlopidine...